Erlonat 150mg Tablet (Erlotinib Hydrochloride)

Erlonat 150mg Tablet contains erlotinib, an oral targeted anticancer medicine known as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It blocks signaling from EGFR, which can reduce the growth and survival of cancer cells that depend on this pathway. Erlotinib 150mg tablets are mainly used in selected patients with non-small cell lung cancer (NSCLC), particularly when the tumor carries a sensitizing EGFR mutation. It has also been used with gemcitabine in selected pancreatic cancer settings according to applicable labels.

Treatment should be based on appropriate molecular testing, previous therapy, and the oncologist’s assessment. Erlonat 150mg Tablet is a prescription medicine. Because food and several medicines can substantially change erlotinib tablet exposure, patients should follow administration instructions carefully and report skin, lung, liver, or gastrointestinal symptoms promptly.

The principal use of the erlotinib tablet is selected locally advanced or metastatic NSCLC with activating EGFR mutations. Depending on the jurisdiction and treatment setting, erlotinib 150mg may be used as initial treatment, maintenance therapy, or after previous systemic treatment when clinically appropriate. Modern NSCLC treatment is highly biomarker driven, so EGFR mutation testing is essential before choosing the erlotinib 150mg tablet for mutation-directed therapy.

Erlotinib 150mg tablet has also been approved in combination with gemcitabine for selected patients with locally advanced, unresectable, or metastatic pancreatic cancer in some regulatory settings. The exact role of the erlotinib 150mg tablet should be determined by an oncologist because newer targeted therapies may be preferred for some EGFR-mutated lung cancers.

Erlotinib is a small-molecule tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR). It binds the intracellular ATP-binding site of EGFR and suppresses downstream signaling pathways that promote tumor cell proliferation and survival. In NSCLC with a sensitizing EGFR mutation, the cancer may be particularly dependent on this signaling pathway, making EGFR inhibition therapeutically useful. This same EGFR blockade in normal skin and gastrointestinal tissues helps explain common effects of the erlotinib 150mg tablet, such as acneiform rash and diarrhea.

Evidence context: The studies below are pivotal or widely cited evidence supporting erlotinib 150mg in major treatment settings. Trial results should not be interpreted as a guarantee of benefit for an individual patient, and exact eligibility must match the current approved indication and oncology guideline.

Erlonat 150mg Tablet may cause side effects, and their frequency varies by indication, dose, combination regimen, and patient population. The list below highlights clinically important effects rather than assigning a single percentage across different trials.

Common side effects

• Acne-like rash
  
• Diarrhea
  
• Reduced appetite
  
• Fatigue
  
• Nausea
  
• Dry skin / itching
  
• Mouth irritation
  

Serious side effects 

• Interstitial lung disease / pneumonitis
  
• Severe diarrhea and dehydration
  
• Severe hepatic injury
  
• Gastrointestinal perforation
  
• Severe skin or ocular reactions
  

The labeled adult dose for metastatic or locally advanced NSCLC is generally 150 mg orally once daily. In pancreatic cancer, the erlotinib 150mg tablet is generally given 150 mg orally once daily in combination with gemcitabine. Take the erlotinib tablet on an empty stomach, at least 1 hour before or 2 hours after food. Dose interruption or reduction may be required for severe rash, diarrhea, liver toxicity, interstitial lung disease, or drug interactions. The erlotinib 150 mg tablet strength does not mean that every patient should receive 150 mg daily; the indication determines the prescribed dose.

Administration guidance: Take the Erlonat 150mg tablet exactly as prescribed, usually once daily. Erlotinib 150mg tablets should generally be taken on an empty stomach, at least 1 hour before or 2 hours after food, because food can increase exposure. Swallow the tablet with water. Take the Erlonat tablet at approximately the same time each day. Do not alter the dose without your oncologist. Acid-reducing medicines can interfere with absorption, so discuss proton-pump inhibitors, H2 blockers, and antacids with the treatment team. Smoking can lower erlotinib tablet exposure and may reduce effectiveness. Regular clinical assessment and laboratory monitoring are required. Contact the oncology team promptly for severe rash, persistent diarrhea, breathlessness, or eye symptoms.

If a dose is missed, do not double the next dose. If it is close to the next scheduled dose, skip the missed dose and resume the usual schedule. If vomiting occurs after a dose, do not automatically repeat it.

Confirm tumor EGFR mutation status for mutation-directed NSCLC use. Monitor liver function, hydration status with significant diarrhea, skin toxicity, and respiratory symptoms. Review smoking status because smoking can reduce erlotinib 150mg tablet exposure. Review acid-suppressive therapy because increased gastric pH can reduce absorption.

Practical monitoring checklist

• Liver function according to baseline risk and treatment label
  

• FDA Tarceva (erlotinib) Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021743s015lbl.pdf​
  
• EMA Tarceva Product Information / SmPC. https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva​
  
• NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. https://pubmed.ncbi.nlm.nih.gov/41956107/​
  
• Healio, non- small cell lung cancer. https://www.healio.com/clinical-guidance/non-small-cell-lung-cancer/nccn-asco-iaslc-and-esmo-guidelines-treatment-guidelines​
  
• IP international journal of comprehensive and advanced pharmacology. Development and validation of RP-HPLC and UV method for erlotinib hydrochloride tablets. https://ijcap.in/archive/volume/6/issue/3/article/3300​